肝硬化患者出凝血系统的变化及凝血功能检测的临床意义

柴诗琦; 陈金军; 祁婷婷

doi:10.3969/j.issn.1001-5256.2021.12.040

肝硬化患者出凝血系统的变化及凝血功能检测的临床意义

DOI: 10.3969/j.issn.1001-5256.2021.12.040

南方医科大学附属南方医院肝病中心，广州 510515

基金项目:

国家科技部重大专项 (2018ZX10723203);

国家科技部重大专项 (2018ZX10302206);

国家自然科学基金 (82070650);

国家重点研发计划 (2017YFC0908100);

广东省珠江人才计划 (2017BT01S131);

广东省省级科技计划项目 (2014B020228003);

广东省省级科技计划项目 (2015B020226004);

南方医科大学临床启动计划 (2020CR026);

南方医科大学临床研究启动计划 (LC2019ZD006);

南方医院院长基金 (2019Z003)

详细信息

通信作者:
陈金军，chjj@smu.edu.cn

祁婷婷，tingtingqi@126.com

中图分类号: R575.2
计量
- 文章访问数: 825
- HTML全文浏览量: 107
- PDF下载量: 111
- 被引次数: 0
出版历程
- 收稿日期: 2021-07-07
- 录用日期: 2021-08-06
- 出版日期: 2021-12-20

Changes in hemostasis and clinical significance of coagulation function test in patients with liver cirrhosis

Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Research funding:

The National Science and Technology Major Project (2018ZX10723203);

The National Science and Technology Major Project (2018ZX10302206);

National Natural Science Foundation of China (82070650);

National Key Research and Development Program of China (2017YFC0908100);

Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01S131);

Department of Science and Technology of Guangdong Province (2014B020228003);

Department of Science and Technology of Guangdong Province (2015B020226004);

Clinical Research Program of Nanfang Hospital, Southern Medical University (2020CR026);

Clinical Research Startup Program of Southern Medical University by High-level University Construction Funding of Guangdong Provincial Department of Education (LC2019ZD006);

President Foundation of Nanfang Hospital, Southern Medical University (2019Z003)

摘要

摘要: 肝脏功能在人体促凝和抗凝机制中非常重要，肝硬化患者的出凝血系统变化极为复杂，且存在门静脉系统与外周系统相互作用及病因学差异，呈现出血与血栓形成的双重态势。目前临床常用的凝血功能检测均存在一定局限性。对肝硬化患者进行抗凝治疗时应综合考虑原发病因，并结合多种检测手段，以期做出最有利于患者的临床决策。
- 肝硬化 /
- 出血 /
- 血液凝固因子 /
- 血液凝固试验
Abstract: The liver plays an important role in procoagulant and anticoagulant mechanisms in human body. There are complex changes in hemostasis in patients with liver cirrhosis, with the presence of interaction between the portal venous system and the peripheral system and differences in etiology, and such patients have a dual trend of hemorrhage and thrombosis. At present, there are certain limitations in coagulation function tests commonly used in clinical practice. The primary etiology and results of various coagulation tests should be considered before initiation of anticoagulant therapy for patients with liver cirrhosis, so as to make the best clinical decisions for patients.
- Liver Cirrhosis /
- Hemorrhage /
- Blood Coagulation Factors /
- Blood Coagulation Tests

HTML全文

参考文献(50)

[1]	O'LEARY JG, GREENBERG CS, PATTON HM, et al. AGA clinical practice update: Coagulation in cirrhosis[J]. Gastroenterology, 2019, 157(1): 34-43. e1. DOI: 10.1053/j.gastro.2019.03.070.
[2]	LATORRE R, VAQUERO J, RINCÓN D, et al. Determinants of platelet count are different in patients with compensated and decompensated cirrhosis[J]. Liver Int, 2016, 36(2): 232-239. DOI: 10.1111/liv.12908.
[3]	AREF S, SLEEM T, EL MENSHAWY N, et al. Antiplatelet antibodies contribute to thrombocytopenia associated with chronic hepatitis C virus infection[J]. Hematology, 2009, 14(5): 277-281. DOI: 10.1179/102453309X439818.
[4]	MITCHELL O, FELDMAN DM, DIAKOW M, et al. The pathophysiology of thrombocytopenia in chronic liver disease[J]. Hepat Med, 2016, 8: 39-50. DOI: 10.2147/HMER.S74612.
[5]	VINHOLT PJ, HVAS AM, NIELSEN C, et al. Reduced platelet activation and platelet aggregation in patients with alcoholic liver cirrhosis[J]. Platelets, 2018, 29(5): 520-527. DOI: 10.1080/09537104.2017.1349308.
[6]	ZHANG H, ZHANG S, ZHANG J, et al. Improvement of human platelet aggregation post-splenectomy with paraesophagogastric devascularization in chronic hepatitis B patients with cirrhotic hypersplenism[J]. Platelets, 2020, 31(8): 1019-1027. DOI: 10.1080/09537104.2019.1704715.
[7]	LISMAN T, BONGERS TN, ADELMEIJER J, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity[J]. Hepatology, 2006, 44(1): 53-61. DOI: 10.1002/hep.21231.
[8]	LISMAN T, ADELMEIJER J, de GROOT PG, et al. No evidence for an intrinsic platelet defect in patients with liver cirrhosis--studies under flow conditions[J]. J Thromb Haemost, 2006, 4(9): 2070-2072. DOI: 10.1111/j.1538-7836.2006.02122.x.
[9]	GROENEVELD DJ, POOLE LG, LUYENDYK JP. Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?[J]. J Thromb Haemost, 2021, 19(6): 1390-1408. DOI: 10.1111/jth.15312.
[10]	BACCOUCHE H, LABIDI A, FEKIH M, et al. Haemostatic balance in cirrhosis[J]. Blood Coagul Fibrinolysis, 2017, 28(2): 139-144. DOI: 10.1097/MBC.0000000000000561.
[11]	PRADHAN-SUNDD T, GUDAPATI S, KAMINSKI TW, et al. Exploring the complex role of coagulation factor Ⅷ in chronic liver disease[J]. Cell Mol Gastroenterol Hepatol, 2021, 12(3): 1061-1072. DOI: 10.1016/j.jcmgh.2021.02.014.
[12]	LEBRETON A, SINEGRE T, PEREIRA B, et al. Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis[J]. J Gastroenterol Hepatol, 2017, 32(4): 916-924. DOI: 10.1111/jgh.13493.
[13]	PATIL AG, BIHARI C, SHEWADE HD, et al. Decreased protein C function predicts mortality in patients with cirrhosis[J]. Int J Lab Hematol, 2018, 40(4): 466-472. DOI: 10.1111/ijlh.12836.
[14]	STEIN SF, HARKER LA. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis[J]. J Lab Clin Med, 1982, 99(2): 217-230.
[15]	HUGENHOLTZ GC, MACRAE F, ADELMEIJER J, et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen[J]. J Thromb Haemost, 2016, 14(5): 1054-1066. DOI: 10.1111/jth.13278.
[16]	GREEN G, POLLER L, THOMSON JM, et al. Association of abnormal fibrin polymerisation with severe liver disease[J]. Gut, 1977, 18(11): 909-912. DOI: 10.1136/gut.18.11.909.
[17]	COLUCCI M, BINETTI BM, BRANCA MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis[J]. Hepatology, 2003, 38(1): 230-237. DOI: 10.1053/jhep.2003.50277.
[18]	RAUTOU PE, BRESSON J, SAINTE-MARIE Y, et al. Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis[J]. Gastroenterology, 2012, 143(1): 166-176. e6. DOI: 10.1053/j.gastro.2012.03.040.
[19]	RAUTOU PE, VION AC, LUYENDYK JP, et al. Circulating microparticle tissue factor activity is increased in patients with cirrhosis[J]. Hepatology, 2014, 60(5): 1793-1795. DOI: 10.1002/hep.27033.
[20]	OWENS AP 3rd, MACKMAN N. Microparticles in hemostasis and thrombosis[J]. Circ Res, 2011, 108(10): 1284-1297. DOI: 10.1161/CIRCRESAHA.110.233056.
[21]	GOULD TJ, VU TT, SWYSTUN LL, et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms[J]. Arterioscler Thromb Vasc Biol, 2014, 34(9): 1977-1984. DOI: 10.1161/ATVBAHA.114.304114.
[22]	AGRAZ-CIBRIAN JM, SEGURA-ORTEGA JE, DELGADO-RIZO V, et al. Alterations in neutrophil extracellular traps is associated with the degree of decompensation of liver cirrhosis[J]. J Infect Dev Ctries, 2016, 10(5): 512-517. DOI: 10.3855/jidc.7165.
[23]	BLASI A, PATEL VC, ADELMEIJER J, et al. Plasma levels of circulating DNA are associated with outcome, but not with activation of coagulation in decompensated cirrhosis and ACLF[J]. JHEP Rep, 2019, 1(3): 179-187. DOI: 10.1016/j.jhepr.2019.06.002.
[24]	STINE JG, WANG J, SHAH PM, et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study[J]. Liver Int, 2018, 38(1): 94-101. DOI: 10.1111/liv.13500.
[25]	QUECK A, CARNEVALE R, USCHNER FE, et al. Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS[J]. Gut, 2020, 69(8): 1535-1536. DOI: 10.1136/gutjnl-2019-319044.
[26]	DELAHOUSSE B, LABAT-DEBELLEIX V, DECALONNE L, et al. Comparative study of coagulation and thrombin generation in the portal and jugular plasma of patients with cirrhosis[J]. Thromb Haemost, 2010, 104(4): 741-749. DOI: 10.1160/TH10-01-0040.
[27]	SHOJAEI S, TAFAZZOLI-SHADPOUR M, SHOKRGOZAR MA, et al. Stress phase angle regulates differentiation of human adipose-derived stem cells toward endothelial phenotype[J]. Prog Biomater, 2018, 7(2): 121-131. DOI: 10.1007/s40204-018-0090-5.
[28]	CARNEVALE R, RAPARELLI V, NOCELLA C, et al. Gut-derived endotoxin stimulates factor Ⅷ secretion from endothelial cells. Implications for hypercoagulability in cirrhosis[J]. J Hepatol, 2017, 67(5): 950-956. DOI: 10.1016/j.jhep.2017.07.002.
[29]	SHALABY S, SIMIONI P, CAMPELLO E, et al. Endothelial damage of the portal vein is associated with heparin-like effect in advanced stages of cirrhosis[J]. Thromb Haemost, 2020, 120(8): 1173-1181. DOI: 10.1055/s-0040-1713169.
[30]	TRIPODI A, MANNUCCI PM. The coagulopathy of chronic liver disease[J]. N Engl J Med, 2011, 365(2): 147-156. DOI: 10.1056/NEJMra1011170.
[31]	ALI M, ANANTHAKRISHNAN AN, MCGINLEY EL, et al. Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: A nationwide analysis[J]. Dig Dis Sci, 2011, 56(7): 2152-2159. DOI: 10.1007/s10620-011-1582-5.
[32]	QI X, REN W, GUO X, et al. Epidemiology of venous thromboembolism in patients with liver diseases: A systematic review and meta-analysis[J]. Intern Emerg Med, 2015, 10(2): 205-217. DOI: 10.1007/s11739-014-1163-7.
[33]	INTAGLIATA NM, CALDWELL SH, TRIPODI A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis[J]. Gastroenterology, 2019, 156(6): 1582-1599. e1. DOI: 10.1053/j.gastro.2019.01.265.
[34]	UNGPRASERT P, WIJARNPREECHA K, THONGPRAYOON C. Risk of cerebrovascular accident in patients with primary biliary cirrhosis: A systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2016, 28(1): 90-94. DOI: 10.1097/MEG.0000000000000493.
[35]	ZHENG K, YOSHIDA EM, TACKE F, et al. Risk of stroke in liver cirrhosis: A systematic review and meta-analysis[J]. J Clin Gastroenterol, 2020, 54(1): 96-105. DOI: 10.1097/MCG.0000000000001201.
[36]	XIONG J, XU W, HUANG H, et al. Cirrhosis and risk of stroke: A systematic review and meta-analysis[J]. Atherosclerosis, 2018, 275: 296-303. DOI: 10.1016/j.atherosclerosis.2018.06.876.
[37]	STINE JG, SHAH PM, CORNELLA SL, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis[J]. World J Hepatol, 2015, 7(27): 2774-2780. DOI: 10.4254/wjh.v7.i27.2774.
[38]	Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis(2020, Shanghai)[J]. J Clin Hepatol, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007. 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海)[J]. 临床肝胆病杂志, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007.
[39]	BOS S, van DEN BOOM B, KAMPHUISEN PW, et al. Haemostatic profiles are similar across all aetiologies of cirrhosis[J]. Thromb Haemost, 2019, 119(2): 246-253. DOI: 10.1055/s-0038-1676954.
[40]	OZER B, SERIN E, SEZGIN N, et al. Thrombopoietin or interleukin-6 has no effect on thrombocytopenia of cirrhosis[J]. Hepatogastroenterology, 2007, 54(76): 1187-1191. http://europepmc.org/abstract/MED/17629067
[41]	MANGIA A, MARGAGLIONE M, CASCAVILLA I, et al. Anticardiolipin antibodies in patients with liver disease[J]. Am J Gastroenterol, 1999, 94(10): 2983-2987. DOI: 10.1111/j.1572-0241.1999.01447.x.
[42]	LI SJ, WANG L, CHEN Z, et al. Association of genotype with cellular immunity and coagulation function in chronic hepatitis B virus infection patients with different disease spectrums in Sichuan, China[J]. J Clin Hepatol, 2020, 36(5): 1014-1018. DOI: 10.3969/j.issn.1001-5256.2020.05.013. 李守娟, 王丽, 陈竹, 等. 四川地区不同疾病谱慢性HBV感染者病毒基因分型与细胞免疫及凝血功能的关系[J]. 临床肝胆病杂志, 2020, 36(5): 1014-1018. DOI: 10.3969/j.issn.1001-5256.2020.05.013.
[43]	XU Y, HUANG XP, CHEN L, et al. Role of coagulation abnormalities in thrombosis in patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(3): 560-564. DOI: 10.3969/j.issn.1001-5256.2021.03.012. 徐英, 黄小平, 陈丽, 等. 凝血异常在HBV相关慢加急性肝衰竭患者血栓形成中的作用[J]. 临床肝胆病杂志, 2021, 37(3): 560-564. DOI: 10.3969/j.issn.1001-5256.2021.03.012.
[44]	GIANNINI EG, STRAVITZ RT, CALDWELL SH. Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis[J]. Hepatology, 2014, 60(4): 1442. DOI: 10.1002/hep.27029.
[45]	TRIPODI A, SALERNO F, CHANTARANGKUL V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests[J]. Hepatology, 2005, 41(3): 553-558. DOI: 10.1002/hep.20569.
[46]	TALON L, SINEGRE T, LECOMPTE T, et al. Hypercoagulability (thrombin generation) in patients with cirrhosis is detected with ST-Genesia[J]. J Thromb Haemost, 2020, 18(9): 2177-2190. DOI: 10.1111/jth.14963.
[47]	CAI TT, LI TX, ZENG W, et al. Study on emergency blood transfusion strategy for traumatic hemorrhagic shock[J]. Trauma Crit Med, 2021, 9(2): 128-131. DOI: 10.16048/j.issn.2095-5561.2021.02.11 蔡婷婷, 李天星, 曾文, 等. 血栓弹力图指导创伤失血性休克急诊输血策略研究[J]. 创伤与急危重病医学, 2021, 9(2): 128-131. DOI: 10.16048/j.issn.2095-5561.2021.02.11.
[48]	COPPELL JA, THALHEIMER U, ZAMBRUNI A, et al. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): An in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays[J]. Blood Coagul Fibrinolysis, 2006, 17(2): 97-104. DOI: 10.1097/01.mbc.0000203859.62739.25.
[49]	DE PIETRI L, BIANCHINI M, MONTALTI R, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial[J]. Hepatology, 2016, 63(2): 566-573. DOI: 10.1002/hep.28148.
[50]	KUMAR M, AHMAD J, MAIWALL R, et al. Thromboelastography-guided blood component use in patients with cirrhosis with nonvariceal bleeding: A randomized controlled trial[J]. Hepatology, 2020, 71(1): 235-246. DOI: 10.1002/hep.30794.